ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
16 September 2024 - 8:50PM
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”)
announced today that the Company has initiated closing logistics
for the previously announced acquisition of Alimera Sciences, Inc.
(Nasdaq: ALIM).
The Company expects closing of the acquisition of Alimera
Sciences to be consummated and announced today, pending
satisfaction or waiver of any remaining customary closing
conditions.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified
biopharmaceutical company serving patients in need by developing,
manufacturing, and marketing high-quality branded and generic
prescription pharmaceutical products, including for diseases with
high unmet medical need. ANI is focused on delivering sustainable
growth by scaling up its Rare Disease business through its lead
asset Purified Cortrophin® Gel, strengthening its Generics business
with enhanced research and development capabilities, delivering
innovation in Established Brands, and leveraging its U.S. based
manufacturing footprint. For more information, visit our
website www.anipharmaceuticals.com.
Forward-Looking Statements
This communication, and the documents to which it refers you,
contains not only historical information, but also forward-looking
statements made pursuant to the safe-harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements represent the parties’ expectations or
beliefs concerning future events, including the timing of the
transaction and other information relating to the transaction.
Forward-looking statements include information concerning the
expected completion and timing of the transaction and other
information relating to the transaction. Without limiting the
foregoing, the words “believes,” “anticipates,” “plans,” “expects,”
“intends,” “forecasts,” “should,” “estimates,” “contemplate,”
“future,” “goal,” “potential,” “predict,” “project,” “projection,”
“may,” “will,” “could,” “should,” “would,” “assuming” and similar
expressions are intended to identify forward-looking statements.
You should read statements that contain these words carefully. They
discuss ANI’s and/or Alimera’s future expectations or state other
forward-looking information and may involve known and unknown risks
over which the parties have no control. Forward-looking statements
speak only as of the date of this communication or the date of any
document incorporated by reference in this document. Further risks
that could cause actual results to differ materially from those
matters expressed in or implied by such forward-looking statements
are described in the parties’ respective SEC reports. Except as
required by applicable law or regulation, neither party undertakes
to update these forward-looking statements to reflect future events
or circumstances.
Investor and/or Media Contacts:Lisa M. Wilson,
In-Site Communications, Inc.212-452-2793lwilson@insitecony.com
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Oct 2024 to Nov 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Nov 2023 to Nov 2024